May 10, 2018 / 1:16 AM / 17 days ago

BRIEF-Aquinox And Astellas Announce Exclusive Licensing Agreement For Rosiptor In Asia-Pacific Region Including Japan

May 9 (Reuters) - Astellas Pharma Inc:

* AQUINOX AND ASTELLAS ANNOUNCE EXCLUSIVE LICENSING AGREEMENT FOR ROSIPTOR IN ASIA-PACIFIC REGION INCLUDING JAPAN

* AQUINOX PHARMACEUTICALS SAYS AQUINOX TO RECEIVE $25 MILLION IN UPFRONT PAYMENT, POTENTIALLY OVER $100 MILLION IN ADDITIONAL MILESTONE PAYMENTS AND ROYALTIES

* AQUINOX- ASTELLAS WILL HAVE EXCLUSIVE RIGHT TO RESEARCH, DEVELOP, COMMERCIALIZE ROSIPTOR FOR ALL HUMAN DISEASES AND CONDITIONS IN JAPAN, OTHER APAC COUNTRIES Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below